Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
April 04 2023 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced that Patrick Yang, PhD, will not seek re-election
to the Codexis Board of Directors. Dr. Yang joined the Board in
2014 and served as the Chair of the Nominating and Corporate
Governance Committee.
“It has been a privilege to have Pat on the Codexis Board. His
expertise in technical operations and manufacturing has been of
tremendous value to the company,” said Byron Dorgan, MBA, Chairman
of the Board of Directors of Codexis. “On behalf of the Board and
the Management Team at Codexis, I would like to thank Pat for his
thoughtful guidance and leadership over his nine years of service
on the Board, which has helped propel the company to where it is
today.”
“We are particularly grateful that Pat’s decision comes after we
have further strengthened our Board of Directors,” said Stephen
Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis.
“With Pat’s partnership, we have ensured continuity of Board
expertise in biomanufacturing with the recent addition of Rahul
Singhvi, MBA, ScD, CEO of National Resilience, Inc., as well as in
gene therapy with the recent addition of Stewart Parker, MBA. We
wish Pat well in all his future endeavors.”
“It has been an exciting time working with Codexis and seeing it
transform into the company it is today,” said Dr. Yang. “The
company is in great hands with this leadership team, and I look
forward to watching their future successes across Life Sciences and
Biotherapeutics.”
About Codexis
Codexis is a leading enzyme engineering company leveraging its
proprietary CodeEvolver® platform to discover and develop
novel, high performance enzymes and biotherapeutics. Codexis
enzymes have applications in the sustainable manufacturing of small
molecule pharmaceuticals, in RNA and DNA synthesis and the creation
of next generation life science tools, and as gene therapies and
oral enzyme therapies. Codexis’ unique enzymes can drive
improvements such as higher yields, reduced energy usage and waste
generation, improved return on capital in manufacturing, improved
sensitivity in genomic and diagnostic applications, and more
efficacious therapeutics. For more information,
visit www.codexis.com.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024